Patents by Inventor E. Douglas KRAMER

E. Douglas KRAMER has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Therapeutic combinations of orally administered irinotecan and a p-gp inhibitor for the treatment of cancer
    Patent number: 11752139
    Abstract: The present disclosure provides pharmaceutical combinations of orally administered irinotecan and a P-gp inhibitor. The pharmaceutical combinations are suitable for the treatment of cancer in a subject and for reducing or preventing toxicity, hypersensitivity-type infusion reactions, and other negative outcomes resulting from or associated with intravenously administered irinotecan (e.g., Camptosar®) therapy in a subject suffering from cancer.
    Type: Grant
    Filed: December 16, 2019
    Date of Patent: September 12, 2023
    Assignee: Athenex HK Innovative Limited
    Inventors: Min-Fun Rudolf Kwan, E. Douglas Kramer, David Lawrence Cutler, Johnson Yiu-Nam Lau, Wing Kai Chan
  • THERAPEUTIC COMBINATIONS OF ORALLY ADMINISTERED PACLITAXEL AND A P-gp INHIBITOR FOR THE TREATMENT OF CANCER
    Publication number: 20230172926
    Abstract: The application pertains to pharmaceutical combinations of orally administered paclitaxel and a P-gp inhibitor. The pharmaceutical combinations are suitable for the treatment of cancer in a subject and for reducing or preventing toxicity, hypersensitivity-type infusion reactions, and other negative outcomes resulting from or associated with intravenously administered paclitaxel (e.g., Taxol® or paclitaxel formulated with Cremophor®) therapy in a subject suffering from cancer.
    Type: Application
    Filed: October 4, 2022
    Publication date: June 8, 2023
    Inventors: Min-Fun Rudolf KWAN, E. Douglas KRAMER, Gerald J. FETTERLY, JR., Cheung-Tak HUNG, Christopher Glyn Charles Alexander JACKSON, Paul William GLUE
  • METHODS OF TREATING AND/OR PREVENTING ACTINIC KERATOSIS
    Publication number: 20230172942
    Abstract: The application pertains to methods of treating and/or preventing actinic keratosis, comprising administering a therapeutically effective amount of KX-01, to a subject in need thereof.
    Type: Application
    Filed: October 11, 2022
    Publication date: June 8, 2023
    Inventors: Min-Fun Rudolf KWAN, Johnson Yiu-Nam LAU, E. Douglas KRAMER, David Lawrence CUTLER, Jane FANG
  • THERAPEUTIC COMBINATIONS OF ORALLY ADMINISTERED DOCETAXEL AND A P-GP INHIBITOR FOR THE TREATMENT OF CANCER
    Publication number: 20230046869
    Abstract: The present disclosure provides pharmaceutical combinations of orally administered docetaxel and a P-gp inhibitor. The pharmaceutical combinations are suitable for the treatment of cancer in a subject and for reducing or preventing toxicity, hypersensitivity-type infusion reactions, and other negative outcomes resulting from or associated with intravenously administered docetaxel (e.g., Taxotere® or docetaxel formulated with polysorbate 80) therapy in a subject suffering from cancer.
    Type: Application
    Filed: June 13, 2022
    Publication date: February 16, 2023
    Inventors: Min-Fun Rudolf KWAN, E. Douglas KRAMER, David Lawrence CUTLER, Johnson Yiu-Nam LAU, Wing Kai CHAN
  • Methods of treating and/or preventing actinic keratosis
    Patent number: 11497750
    Abstract: The application pertains to methods of treating and/or preventing actinic keratosis, comprising administering a therapeutically effective amount of KX-01, to a subject in need thereof.
    Type: Grant
    Filed: February 28, 2020
    Date of Patent: November 15, 2022
    Assignee: ATNX SPV, LLC
    Inventors: Min-Fun Rudolf Kwan, Johnson Yiu-Nam Lau, E. Douglas Kramer, David Lawrence Cutler, Jane Fang
  • Therapeutic combinations of orally administered docetaxel and a P-gp inhibitor for the treatment of cancer
    Patent number: 11389442
    Abstract: The present disclosure provides pharmaceutical combinations of orally administered docetaxel and a P-gp inhibitor. The pharmaceutical combinations are suitable for the treatment of cancer in a subject and for reducing or preventing toxicity, hypersensitivity-type infusion reactions, and other negative outcomes resulting from or associated with intravenously administered docetaxel (e.g., Taxotere® or docetaxel formulated with polysorbate 80) therapy in a subject suffering from cancer.
    Type: Grant
    Filed: October 29, 2020
    Date of Patent: July 19, 2022
    Assignee: Athenex HK Innovative Limited
    Inventors: Min-Fun Rudolf Kwan, E. Douglas Kramer, David Lawrence Cutler, Johnson Yiu-Nam Lau, Wing Kai Chan
  • THERAPEUTIC COMBINATIONS OF ORALLY ADMINISTERED DOCETAXEL AND A P-GP INHIBITOR FOR THE TREATMENT OF CANCER
    Publication number: 20210290614
    Abstract: The present disclosure provides pharmaceutical combinations of orally administered docetaxel and a P-gp inhibitor. The pharmaceutical combinations are suitable for the treatment of cancer in a subject and for reducing or preventing toxicity, hypersensitivity-type infusion reactions, and other negative outcomes resulting from or associated with intravenously administered docetaxel (e.g., Taxotere® or docetaxel formulated with polysorbate 80) therapy in a subject suffering from cancer.
    Type: Application
    Filed: October 29, 2020
    Publication date: September 23, 2021
    Inventors: Min-Fun Rudolf KWAN, E. Douglas KRAMER, David Lawrence CUTLER, Johnson Yiu-Nam LAU, Wing Kai CHAN
  • Therapeutic combinations of orally administered docetaxel and a P-gp inhibitor for the treatment of cancer
    Patent number: 10849893
    Abstract: The present disclosure provides pharmaceutical combinations of orally administered docetaxel and a P-gp inhibitor. The pharmaceutical combinations are suitable for the treatment of cancer in a subject and for reducing or preventing toxicity, hypersensitivity-type infusion reactions, and other negative outcomes resulting from or associated with intravenously administered docetaxel (e.g., Taxotere® or docetaxel formulated with polysorbate 80) therapy in a subject suffering from cancer.
    Type: Grant
    Filed: December 16, 2019
    Date of Patent: December 1, 2020
    Assignee: Athenex HK Innovative Limited
    Inventors: Min-Fun Rudolf Kwan, E. Douglas Kramer, David Lawrence Cutler, Johnson Yiu-Nam Lau, Wing Kai Chan
  • METHODS OF TREATING AND/OR PREVENTING ACTINIC KERATOSIS
    Publication number: 20200197405
    Abstract: The application pertains to methods of treating and/or preventing actinic keratosis, comprising administering a therapeutically effective amount of KX-01, to a subject in need thereof.
    Type: Application
    Filed: February 28, 2020
    Publication date: June 25, 2020
    Inventors: Min-Fun Rudolf Kwan, Johnson Yiu-Nam Lau, E. Douglas Kramer, David Lawrence Cutler, Jane Fang
  • THERAPEUTIC COMBINATIONS OF ORALLY ADMINISTERED DOCETAXEL AND A P-GP INHIBITOR FOR THE TREATMENT OF CANCER
    Publication number: 20200188386
    Abstract: The present disclosure provides pharmaceutical combinations of orally administered docetaxel and a P-gp inhibitor. The pharmaceutical combinations are suitable for the treatment of cancer in a subject and for reducing or preventing toxicity, hypersensitivity-type infusion reactions, and other negative outcomes resulting from or associated with intravenously administered docetaxel (e.g., Taxotere® or docetaxel formulated with polysorbate 80) therapy in a subject suffering from cancer.
    Type: Application
    Filed: December 16, 2019
    Publication date: June 18, 2020
    Inventors: Min-Fun Rudolf KWAN, E. Douglas KRAMER, David Lawrence CUTLER, Johnson Yiu-Nam LAU, Wing Kai CHAN
  • THERAPEUTIC COMBINATIONS OF ORALLY ADMINISTERED IRINOTECAN AND A P-GP INHIBITOR FOR THE TREATMENT OF CANCER
    Publication number: 20200188363
    Abstract: The present disclosure provides pharmaceutical combinations of orally administered irinotecan and a P-gp inhibitor. The pharmaceutical combinations are suitable for the treatment of cancer in a subject and for reducing or preventing toxicity, hypersensitivity-type infusion reactions, and other negative outcomes resulting from or associated with intravenously administered irinotecan (e.g., Camptosar®) therapy in a subject suffering from cancer.
    Type: Application
    Filed: December 16, 2019
    Publication date: June 18, 2020
    Inventors: Min-Fun Rudolf KWAN, E. Douglas KRAMER, David Lawrence CUTLER, Johnson Yiu-Nam LAU, Wing Kai CHAN
  • Methods of treating and/or preventing actinic keratosis
    Patent number: 10617693
    Abstract: The application pertains to methods of treating and/or preventing actinic keratosis, comprising administering a therapeutically effective amount of KX-01, to a subject in need thereof.
    Type: Grant
    Filed: March 12, 2018
    Date of Patent: April 14, 2020
    Assignee: Athenex, Inc.
    Inventors: Min-Fun Rudolf Kwan, Johnson Yiu-Nam Lau, E. Douglas Kramer, David Lawrence Cutler, Jane Fang
  • METHODS OF TREATING AND/OR PREVENTING ACTINIC KERATOSIS
    Publication number: 20180256589
    Abstract: The application pertains to methods of treating and/or preventing actinic keratosis, comprising administering a therapeutically effective amount of KX-01, to a subject in need thereof.
    Type: Application
    Filed: March 12, 2018
    Publication date: September 13, 2018
    Inventors: Min-Fun Rudolf KWAN, Johnson Yiu-Nam LAU, E. Douglas KRAMER, David Lawrence CUTLER, Jane FANG
  • THERAPEUTIC COMBINATIONS OF ORALLY ADMINISTERED PACLITAXEL AND A P-gp INHIBITOR FOR THE TREATMENT OF CANCER
    Publication number: 20180207148
    Abstract: The application pertains to pharmaceutical combinations of orally administered paclitaxel and a P-gp inhibitor. The pharmaceutical combinations are suitable for the treatment of cancer in a subject and for reducing or preventing toxicity, hypersensitivity-type infusion reactions, and other negative outcomes resulting from or associated with intravenously administered paclitaxel (e.g., Taxol® or paclitaxel formulated with Cremophor®) therapy in a subject suffering from cancer.
    Type: Application
    Filed: July 21, 2016
    Publication date: July 26, 2018
    Inventors: Min-Fun Rudolf KWAN, E. Douglas KRAMER, Gerald J. FETTERLY, Jr., Cheung-Tak HUNG, Christopher Glyn Charles Alexander JACKSON, Paul William GLUE